Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology and Hepatology
Volume 2018, Article ID 9430953, 9 pages
https://doi.org/10.1155/2018/9430953
Research Article

Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis

1Department of Medicine, North Shore Medical Center, Salem, MA, USA
2Department of Medicine, University of Massachusetts Medical School, Worcester MA, USA
3School of Public Health, University of Massachusetts Lowell, Lowell, MA, USA
4Department of Medicine, Englewood Hospital and Medical Center, Englewood, NJ, USA
5INRS-Institut Armand-Frappier, Institut National de la Recherche Scientifique, Laval, QC, Canada

Correspondence should be addressed to Terence Ndonyi Bukong; ac.srni.fai@gnokub.iynodnecneret

Received 1 May 2018; Revised 13 August 2018; Accepted 29 August 2018; Published 23 September 2018

Academic Editor: Pierluigi Toniutto

Copyright © 2018 Adeyinka Charles Adejumo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Goldberg, I. C. Ditah, K. Saeian et al., “Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation,” Gastroenterology, vol. 152, no. 5, pp. 1090–1099.e1, 2017. View at Publisher · View at Google Scholar · View at Scopus
  2. “Snapshot,” 2017, http://onlinelibrary.wiley.com/doi/10.1111/jvh.12262/abstract.
  3. C. Welsch, A. Jesudian, S. Zeuzem, and I. Jacobson, “New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives,” Gut, vol. 61, no. 1, pp. i36–i46, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Zeuzem, R. Ghalib, K. R. Reddy et al., “Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial,” Annals of Internal Medicine, vol. 163, no. 1, pp. 1–13, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. K. A. Forde, O. Tanapanpanit, and K. R. Reddy, “Hepatitis B and C in African Americans: Current status and continued challenges,” Clinical Gastroenterology and Hepatology, vol. 12, no. 5, pp. 738–748, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Lemoine, S. Nayagam, and M. Thursz, “Viral hepatitis in resource-limited countries and access to antiviral therapies: Current and future challenges,” Future Virology, vol. 8, no. 4, pp. 371–380, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Azofeifa, M. E. Mattson, G. Schauer, T. McAfee, A. Grant, and R. Lyerla, “National Estimates of Marijuana Use and Related Indicators — National Survey on Drug Use and Health, United States, 2002–2014,” MMWR Surveillance Summaries, vol. 65, no. 11, pp. 1–28, 2016. View at Publisher · View at Google Scholar
  8. E. Gabbay, Y. Avraham, Y. Ilan, E. Israeli, and E. M. Berry, “Endocannabinoids and liver disease - Review,” Liver International, vol. 25, no. 5, pp. 921–926, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Patsenker, P. Sachse, A. Chicca et al., “Elevated levels of endocannabinoids in chronic hepatitis c may modulate cellular immune response and hepatic stellate cell activation,” International Journal of Molecular Sciences, vol. 16, no. 4, pp. 7057–7076, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. A. C. Adejumo, S. Alliu, T. O. Ajayi et al., “Cannabis use is associated with reduced prevalence of non-alcoholic fatty liver disease: A cross-sectional study,” PLoS ONE, vol. 12, no. 4, 2017. View at Google Scholar · View at Scopus
  11. A. C. Adejumo, T. O. Ajayi, O. M. Adegbala et al., “Cannabis use is associated with reduced prevalence of progressive stages of alcoholic liver disease,” Liver International, 2018. View at Google Scholar · View at Scopus
  12. C. Hézode, F. Roudot-Thoraval, S. Nguyen et al., “Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C,” Hepatology, vol. 42, no. 1, pp. 63–71, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Hézode, E. S. Zafrani, F. Roudot-Thoraval et al., “Daily cannabis Use: a novel risk factor of steatosis severity in patients with chronic hepatitis C,” Gastroenterology, vol. 134, no. 2, pp. 432–439, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. J. H. Ishida, M. G. Peters, C. Jin et al., “Influence of Cannabis Use on Severity of Hepatitis C Disease,” Clinical Gastroenterology and Hepatology, vol. 6, no. 1, pp. 69–75, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Brunet, E. E. M. Moodie, K. Rollet et al., “Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: A longitudinal Cohort analysis,” Clinical Infectious Diseases, vol. 57, no. 5, pp. 663–670, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. Theresa Liu, G. T. Howell, Lucy Turner, Kimberley Corace, Gary Garber, and Curtis Cooper, “Marijuana Use in Hepatitis C Infection does not Affect Liver Biopsy Histology or Treatment Outcomes,” Canadian Journal of Gastroenterology and Hepatology, vol. 28, Article ID 804969, 4 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Kelly, J. Dodge, M. Sarkar et al., “Marijuana Use Is Not Associated With Progression to Advanced Liver Fibrosis in HIV/Hepatitis C Virus–coinfected Women,” Clin Infect Dis, vol. 63, no. 4, pp. 512–518, 2016. View at Google Scholar
  18. S. Nordmann, A. Vilotitch, P. Roux et al., “Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus-co-infected patients (ANRS CO13-HEPAVIH),” Journal of Viral Hepatitis, vol. 25, no. 2, pp. 171–179, 2018. View at Publisher · View at Google Scholar
  19. H. Lowe, N. Toyang, and W. McLaughlin, “Potential of cannabidiol for the treatment of viral hepatitis,” Pharmacognosy Research, vol. 9, no. 1, pp. 116–118, 2017. View at Publisher · View at Google Scholar · View at Scopus
  20. “Citations for HCUP Databases and Tools,” 2017, https://www.hcup-us.ahrq.gov/tech_assist/citations.jsp.
  21. Z. M. Younossi, M. Otgonsuren, L. Henry et al., “Inpatient resource utilization, disease severity, mortality and insurance coverage for patients hospitalized for hepatitis C virus in the United States,” Journal of Viral Hepatitis, vol. 22, no. 2, pp. 137–145, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. A. N. Ananthakrishnan, E. L. McGinley, J. Fangman, and K. Saeian, “Hepatitis C/HIV co-infection is associated with higher mortality in hospitalized patients with Hepatitis C or HIV,” Journal of Viral Hepatitis, vol. 17, no. 10, pp. 720–729, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Rajbhandari, C. J. Danford, R. T. Chung, and A. N. Ananthakrishnan, “HBV infection is associated with greater mortality in hospitalised patients compared to HCV infection or alcoholic liver disease,” Alimentary Pharmacology & Therapeutics, vol. 41, no. 10, pp. 928–938, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. A. J. Kruger, K. Mumtaz, A. Anaizi et al., “Cirrhosis Is Associated with Increased Mortality in Patients with Diverticulitis: A Nationwide Cross-Sectional Study,” Digestive Diseases and Sciences, vol. 62, no. 11, pp. 3149–3155, 2017. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Wu and G. C. Nguyen, “Liver cirrhosis is associated with venous thromboembolism among hospitalized patients in a nationwide US study,” Clinical Gastroenterology and Hepatology, vol. 8, no. 9, pp. 800–e1, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Hammill, “GMATCH SAS macro: computerized matching of cases to controls using the greedy matching algorithm with a fixed number of controls per case,” 2015, http://people.duke.edu/~hammill/software/gmatch.sas.
  27. I. J. Dahabreh, R. C. Sheldrick, J. K. Paulus et al., “Do observational studies using propensity score methods agree with randomized trials? A systematic comparison of studies on acute coronary syndromes,” European Heart Journal, vol. 33, no. 15, pp. 1893–1901, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. G. D. Kitsios, I. J. Dahabreh, S. Callahan, J. K. Paulus, A. C. Campagna, and J. M. Dargin, “Can We Trust Observational Studies Using Propensity Scores in the Critical Care Literature? A Systematic Comparison with Randomized Clinical Trials,” Critical Care Medicine, vol. 43, no. 9, pp. 1870–1879, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Spiegelman and E. Hertzmark, “Easy SAS calculations for risk or prevalence ratios and differences,” American Journal of Epidemiology, vol. 162, no. 3, pp. 199-200, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. D. van der Poorten, M. Shahidi, E. Tay et al., “Hepatitis C Virus Induces the Cannabinoid Receptor 1,” PLoS ONE, vol. 5, no. 9, p. e12841, 2010. View at Publisher · View at Google Scholar
  31. B. Julien, P. Grenard, F. Teixeira-Clerc et al., “Antifibrogenic role of the cannabinoid receptor CB2 in the liver,” Gastroenterology, vol. 128, no. 3, pp. 742–755, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Muñoz-Luque, J. Ros, G. Fernández-Varo et al., “Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats,” The Journal of Pharmacology and Experimental Therapeutics, vol. 324, no. 2, pp. 475–483, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. F. Borrelli, E. Pagano, B. Romano et al., “Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid,” Carcinogenesis, vol. 35, no. 12, pp. 2787–2797, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Guzman, M. J. Duarte, C. Blázquez et al., “A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme,” British Journal of Cancer, vol. 95, no. 2, pp. 197–203, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. N. Vin-Raviv, T. Akinyemiju, Q. Meng, S. Sakhuja, and R. Hayward, “Marijuana use and inpatient outcomes among hospitalized patients: analysis of the nationwide inpatient sample database,” Cancer Medicine, vol. 6, no. 1, pp. 320–329, 2017. View at Publisher · View at Google Scholar · View at Scopus
  36. D. L. Sylvestre, B. J. Clements, and Y. Malibu, “Cannabis use improves retention and virological outcomes in patients treated for hepatitis C,” European Journal of Gastroenterology & Hepatology, vol. 18, no. 10, pp. 1057–1063, 2006. View at Publisher · View at Google Scholar · View at Scopus